2021
DOI: 10.1021/acs.oprd.0c00544
|View full text |Cite
|
Sign up to set email alerts
|

Development and Scale-Up of an Asymmetric Synthesis Process for Alogliptin

Abstract: Alogliptin (1) benzoate is a potent, highly selective inhibitor of serine protease dipeptidyl-peptidase IV, approved by US FDA for the treatment of type 2 diabetes. Herein, we report a more cost-effective process that includes ruthenium-catalyzed asymmetric hydrogenation followed by Hofmann rearrangement of 2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1­(2H)-yl)­methyl)­benzonitrile (10) to introduce a chiral amino moiety at a late stage. Use of an inexpensive and readily available nicotinamide (6) for… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
5
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
4
3

Relationship

0
7

Authors

Journals

citations
Cited by 8 publications
(5 citation statements)
references
References 14 publications
0
5
0
Order By: Relevance
“…Application of this reaction can be found in the production of alogliptin ( 138 ). The Ru/BINAP catalyzed asymmetric hydrogenation of prochiral tetrahydropyridine salt 136 , which was obtained from nicotinamide by Pd/C -catalyzed hydrogenation, led to chiral intermediate 137 in 68% yield and 99.7% ee after recrystallization (Scheme a) …”
Section: Asymmetric Transition Metal Catalysismentioning
confidence: 99%
See 1 more Smart Citation
“…Application of this reaction can be found in the production of alogliptin ( 138 ). The Ru/BINAP catalyzed asymmetric hydrogenation of prochiral tetrahydropyridine salt 136 , which was obtained from nicotinamide by Pd/C -catalyzed hydrogenation, led to chiral intermediate 137 in 68% yield and 99.7% ee after recrystallization (Scheme a) …”
Section: Asymmetric Transition Metal Catalysismentioning
confidence: 99%
“…The Ru/ BINAP catalyzed asymmetric hydrogenation of prochiral tetrahydropyridine salt 136, which was obtained from nicotinamide by Pd/C -catalyzed hydrogenation, led to chiral intermediate 137 in 68% yield and 99.7% ee after recrystallization (Scheme 29a). 87 Enantiomerically pure fluoro-containing molecules are important intermediates for the synthesis of active pharmaceutical ingredients due to their improved physiological properties. In the synthesis of AZD9742 (141) containing a cis-4-amino-3fluoropiperidine moiety, the asymmetric hydrogenation was performed on tetrasubstituted enamide 139, which was obtained from the reduction of the corresponding pyridinium salt with NaBH 4 (Scheme 29b).…”
Section: Asymmetric (Transfer) Hydrogenationmentioning
confidence: 99%
“…Nitrogen-containing heterocycles are present in several valuable bioactive compounds, such as piracetam ( 50) [132], anisomycin (51) [133], and alogliptin (52) [134] (Scheme 20A).…”
Section: Manganese-catalyzed C-h Activationmentioning
confidence: 99%
“…Asymmetric hydrogenation of 6b using RuCl 2 (s-binap) as the catalyst led to amido ester 14 in 65% yield with 95:5 er. 17 Removal of the Boc group followed by N-alkylation with homoallylic bromide delivered 15 in 72% yield. Subsequent hydrolysis of the ester group and treatment with aqueous HCl gave sila-tiagabine 16 in 85% yield with 95:5 er, indicating that both silicon and chiral carbon moieties were well-tolerated under a series of strongly basic and acidic conditions in this approach.…”
mentioning
confidence: 99%
“…We further carried out the synthesis of the sila analogue of tiagabine, a well-known antiepileptic drug. Asymmetric hydrogenation of 6b using RuCl 2 (s-binap) as the catalyst led to amido ester 14 in 65% yield with 95:5 er . Removal of the Boc group followed by N -alkylation with homoallylic bromide delivered 15 in 72% yield.…”
mentioning
confidence: 99%